Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 96267
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96267
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96267
Table 3 Treatment-related adverse events, n (%)
| Adverse events | TACE + SL (n = 30) | TACE + L (n = 27) | ||||
| Toxicity grade | / | 1/2 | 3/4 | / | 1/2 | 3/4 |
| Diarrhea | 6 (20.0) | 4 | 2 | 5 (18.5) | 3 | 2 |
| Transaminitis | 14 (46.7) | 12 | 2 | 13 (48.1) | 8 | 5 |
| Hand-foot skin reactions | 10 (33.3) | 7 | 3 | 7 (25.9) | 6 | 1 |
| Nausea with/without vomiting | 23 (76.7) | 20 | 3 | 17 (63.0) | 15 | 2 |
| Abdominal pain | 22 (73.3) | 18 | 4 | 22 (81.5) | 19 | 3 |
| Fatigue | 9 (30.0) | 6 | 3 | 7 (25.9) | 5 | 2 |
| Fever | 23 (76.7) | 20 | 3 | 17 (63.0) | 15 | 2 |
| Decreased WBC/PLT count | 7 (23.3) | 5 | 2 | 9 (33.3) | 7 | 2 |
| Thrombopenia | 8 (26.7) | 7 | 1 | 3 (11.1) | 2 | 1 |
| Decreased appetite | 5 (16.7) | 5 | 0 | 8 (30.0) | 8 | 0 |
| Hypertension | 12 (40.0) | 9 | 3 | 7 (26.0) | 4 | 3 |
| Hypothyroidism | 7 (23.3) | 6 | 1 | / | / | / |
| Proteinuria | 0 (0.0) | 0 | 0 | 1 (3.7) | 0 | 1 |
- Citation: Wu FD, Zhou HF, Yang W, Zhu D, Wu BF, Shi HB, Liu S, Zhou WZ. Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(1): 96267
- URL: https://www.wjgnet.com/1948-5204/full/v17/i1/96267.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i1.96267